Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 39 Colonic Neoplasms 14 Colorectal Neoplasms 13 Neoplasms 12 Rectal Neoplasms 11 Prostatic Neoplasms 11 Carcinoma, Non-Small-Cell Lung 10 Uterine Cervical Neoplasms 8 Obesity 8 Motor Activity 8 Lung Neoplasms 8 Endometrial Neoplasms 8 Tobacco Use Disorder 6 Small Cell Lung Carcinoma 6 Overweight 6 Depression 6 Pancreatic Neoplasms 5 Ovarian Neoplasms 5 Leukemia, Myeloid, Acute 5 Fatigue 5 Breast Carcinoma In Situ 5 Anxiety Disorders 5 Urinary Bladder Neoplasms 4 Sexuality 4 Sexual Dysfunction, Physiological 4 Leukemia 4 Head and Neck Neoplasms 4 Carcinoma, Renal Cell 4 Carcinoma, Intraductal, Noninfiltrating 4 Body Weight Changes 4

Interventions

Megestrol Acetate 9 Exercise 6 Standard of Care 4 Blood Specimen Collection 4 Olanzapine 3 Ibuprofen 3 dermcidin 2 anamorelin 2 Resistance Training 2 Physical Therapy Modalities 2 Nutrition Assessment 2 Mirtazapine 2 Melatonin 2 Infliximab 2 Enteral Nutrition 2 Dietary Supplements 2 Diet Therapy 2 Cyproheptadine 2 testosterone enanthate 1 telotristat ethyl 1 remune 1 ostarine 1 olanzapine-fluoxetine combination 1 nabiximols 1 nabilone 1 irinotecan sucrosofate 1 fucoidan 1 clazakizumab 1 bermekimab 1 alkaloid GB18 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Cachexia × Counseling × Clear all

NCT02330926 2025-08-29

MENAC

Norwegian University of Science and Technology

Phase 3 Completed

Cachexia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡